(Lebanon, NH, 11/5/2012) — Dartmouth researchers have found that duration of ibuprofen use was associated with a reduced risk of bladder cancer in patients in northern New England, which has a high mortality rate of this disease. In a 2012 collaborative project with the National Cancer Institute, Margaret Karagas, PhD, co-director, Cancer Epidemiology & Chemoprevention program at Norris Cotton Cancer Center, and Professor of Community and Family Medicine at the Geisel School of Medicine at Dartmouth, and Richard Waddell, D.Sc, Research Assistant Professor of Medicine at the Geisel School of Medicine, looked for connections between ibuprofen use and bladder cancer.
Bladder cancer and ibuprofen use
Karagas did an earlier study on the relationship between bladder cancer and nonsteroidal anti-inflammatory drugs (NSAIDs) usage in New Hampshire. The new study included patients in Vermont and Maine. Researchers enrolled 1,171 participants newly diagnosed with bladder cancer and 1,418 participants who did not have bladder cancer. Karagas also added a genetic component looking at thirty-nine genes related to NSAID metabolism and studied a new class of NSAIDs known as selective cyclooxygenase (COX-2) inhibitors, such as celecoxib (Celebrex). Their results were published in the International Journal of Cancer (June 2012).
Those with specific genetic traits appear to have reduced risk
The findings in the recent study suggest that "regular use of nonaspirin nonselective NSAIDs, particularly ibuprofen, may reduce bladder cancer risk, especially among regular users for 10 years or more." However, the study also notes that observed reduction in risk was specific to individuals carrying a specific allele (or variant of a gene) related to NSAID metabolism.
Findings suggest further study needed for newer prescription pain reliever
For Karagas one of the novel findings was a trend of an increased risk of bladder cancer for those using selective COX-2 inhibitors, especially celocoxib (Celebrex). Karagas warns against leaping to any conclusions, noting, "further investigation is needed."
Karagas also stresses that this study "does not make any recommendations. It does not, in any way, suggest that patients begin taking ibuprofen as a prophylactic measure against bladder cancer, nor should patients go off any medicine prescribed by their doctor."
This research study was funded by the National Institutes of Health Grant number: N02-CP-01037
About Norris Cotton Cancer Center at Dartmouth-Hitchcock
Norris Cotton Cancer Center combines advanced cancer research at Dartmouth College and the Geisel School of Medicine at Dartmouth with patient-centered cancer care provided at Dartmouth-Hitchcock Medical Center, at Dartmouth-Hitchcock regional locations in Manchester, Nashua, and Keene, NH, and St. Johnsbury, VT, and at 12 partner hospitals throughout New Hampshire and Vermont. It is one of 41 centers nationwide to earn the National Cancer Institute's "Comprehensive Cancer Center" designation. Learn more about Norris Cotton Cancer Center research, programs, and clinical trials online at cancer.dartmouth.edu.
Journal
International Journal of Cancer